Black Diamond Therapeutics (BDTX) CSO gets 250,000 stock options

Rhea-AI Filing Summary

Black Diamond Therapeutics, Inc. reported that its Chief Scientific Officer, Elizabeth Buck, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $2.57 per share and were granted on January 21, 2026, with an expiration date of January 20, 2036. According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on her continued service. Following this grant, she holds 250,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Buck Elizabeth

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buck Elizabeth

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.57	01/21/2026		A		250,000		(1)	01/20/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BDTX report for its Chief Scientific Officer?

Black Diamond Therapeutics, Inc. reported that its Chief Scientific Officer, Elizabeth Buck, received a grant of stock options for 250,000 shares of common stock.

What is the exercise price of the Elizabeth Buck stock options at BDTX?

The stock options granted to Elizabeth Buck have an exercise price of $2.57 per share for Black Diamond Therapeutics, Inc. common stock.

How do the BDTX stock options granted to the CSO vest?

For the Black Diamond Therapeutics, Inc. grant, 25% of the option shares vest on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to her continued service.

When do the Elizabeth Buck stock options at Black Diamond Therapeutics expire?

The stock options granted to Elizabeth Buck by Black Diamond Therapeutics, Inc. have an expiration date of January 20, 2036.

How many derivative securities does the BDTX CSO hold after this Form 4 transaction?

After the reported transaction, Elizabeth Buck beneficially owns 250,000 stock options directly, according to the Form 4 for Black Diamond Therapeutics, Inc.

Is the BDTX Chief Scientific Officer a director or 10% owner based on this filing?

Based on the Form 4, Elizabeth Buck is reported as an officer (Chief Scientific Officer) of Black Diamond Therapeutics, Inc., and not as a director or 10% owner.